Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Narcolepsy is a chronic sleep disorder characterized mainly by excessive daytime sleepiness (EDS) and cataplexy in the case of narcolepsy type 1 (NT1). Pitolisant is a histamine 3 receptor antagonist/inverse agonist that reduces EDS and cataplexy in patients with narcolepsy.
Methods: We performed a prospective 5-year follow-up, non-interventional study of adults with NT1 and NT2 receiving pitolisant. The primary objectives were to collect information on the long-term safety of pitolisant and analyze the utilization patterns of pitolisant. The secondary objectives were to assess clinical benefit, adherence, impact on patients' quality of life, disease burden, and patient satisfaction. We reported the results of an interim analysis after 42.6 months.
Results: The population comprised 370 patients (mean age, 40 ± 15 years; 51.4 % women; NT1, 71.4 %; NT2, 28.6 %); 364 received ≥1 dose of pitolisant. Data were available for 356 patients (97.8 %). Most patients (68.4 %) had ≥1 comorbidity (obesity [BMI≥30], 31.9 %; neuropsychiatric, 31 %; and cardiovascular, 22.8 %). Forty-eight patients (13.2 %) had received no prior narcoleptic treatment, while 98 (31 %) were taking a previous therapy, which was switched to pitolisant. Treatment was combined with pitolisant in 218 (69 %) patients. Pitolisant was discontinued by 131 patients (35.4 %), mainly for safety reasons (14.3 %), lack of response (8.7 %), and patient decision (7.6 %). Overall, 355 treatment-emergent adverse events (3 serious) were reported by 156 patients (42.9 % of safety population), with 218 possibly treatment-related (61.4 %) in 109 patients (29.9 %). Improvements were observed in EDS, cataplexy, and quality of life.
Conclusions: Pitolisant was generally safe and well tolerated in patients with NT1 and NT2 and can be used in both types. Improvements were found in EDS, cataplexy, and quality of life, with good adherence and satisfaction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.sleep.2025.02.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dissolution of Once-Nightly Sodium Oxybate in Soft Foods and Alternative Liquid Reconstitution Vehicles.
Clin Ther
September 2025
Avadel Pharmaceuticals, Chesterfield, Missouri.
Purpose: Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness (EDS) and can occur with or without cataplexy. Once-nightly sodium oxybate (ON-SXB) is approved for the treatment of cataplexy or EDS in patients 7 years of age or older with narcolepsy. ON-SXB contains both immediate-release and pH-dependent, controlled-release granules designed to be reconstituted in water and administered orally once at bedtime.
View Article and Find Full Text PDFThe burden of narcolepsy symptoms from patients' perspective: a narrative qualitative study.
Sleep Breath
July 2025
Faculty of Medicine, Department of Neurology, Pavol Jozef Safarik University in Kosice, Kosice, Slovakia.
Background: Narcolepsy is characterized by excessive daytime sleepiness (EDS) and, in type one, cataplexy, often accompanied by disrupted nocturnal sleep, parasomnias, and other impairments. This study aims to explore patients' perceptions and emotional experiences of these symptoms.
Methods: A qualitative study was conducted using narrative semi-structured interviews with 25 narcolepsy patients, guided by a structure approved by a multidisciplinary expert board.
Meditation as a non-pharmacological treatment for narcolepsy: A literature review.
Sleep Med
September 2025
Depression Clinical and Research Program, Massachusetts General Hospital, One Bowdoin Square, Boston, MA, 02114, USA; Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA; South Cove Community Health Center, 145 South St., Boston, MA, 02111, USA. Electronic address:
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, and hallucinations, and is often associated with other psychological and physiological disturbances. These symptoms lead to decreased social functioning and lower quality of life for individuals with narcolepsy. While current pharmacological treatment for narcolepsy can be effective in improving symptoms, there are also significant side effects (e.
View Article and Find Full Text PDFNarcolepsy and cardiovascular health: A big picture perspective.
Sleep Med
September 2025
Avadel Pharmaceuticals, Chesterfield, MO, USA. Electronic address:
Narcolepsy is an uncommon, chronic neurologic disorder characterized by pervasive excessive daytime sleepiness (EDS) that can occur with cataplexy (narcolepsy type 1) or without cataplexy (narcolepsy type 2). People with narcolepsy have an increased risk of comorbid psychiatric disorders and primary sleep disorders, as well as increased healthcare utilization compared to the general population. Over the past several years, clinicians and patients in the narcolepsy community have frequently received communications regarding cardiovascular disease (CVD) risk but disproportionately inadequate information regarding proactive steps to promote cardiovascular (CV) health.
View Article and Find Full Text PDFDiscovery of a New Class of Orexin 2 Receptor Agonists as a Potential Treatment for Narcolepsy.
J Med Chem
May 2025
Idorsia Pharmaceuticals Limited, Hegenheimermattweg 91, Allschwil CH-4123, Switzerland.
The orexinergic system, projecting from the lateral hypothalamus, operates through two receptors, orexin receptor type-1 (OX) and orexin receptor type-2 (OX), stabilizing wakefulness, mainly via OX. Narcolepsy Type 1 (NT1) is characterized by excessive sleepiness and cataplexy, and is linked to a loss of orexin-producing neurons. Current therapies manage the symptoms but do not address the underlying cause of the disease.
View Article and Find Full Text PDF